Research Analysts Offer Predictions for KTTA Q4 Earnings

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Equities research analysts at HC Wainwright decreased their Q4 2026 earnings per share estimates for Pasithea Therapeutics in a note issued to investors on Monday, August 17th. HC Wainwright analyst S. Nik now forecasts that the company will earn ($0.25) per share for the quarter, down from their previous estimate of ($0.24). HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Pasithea Therapeutics’ current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Pasithea Therapeutics’ FY2027 earnings at ($0.46) EPS and FY2028 earnings at ($0.55) EPS.

A number of other research firms have also recently commented on KTTA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Wednesday, June 24th. Zacks Research downgraded Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.00.

Pasithea Therapeutics Trading Up 4.1%

NASDAQ KTTA opened at $0.50 on Wednesday. The firm’s fifty day moving average price is $0.50 and its two-hundred day moving average price is $0.67. Pasithea Therapeutics has a 1 year low of $0.28 and a 1 year high of $2.06. The firm has a market capitalization of $16.63 million, a P/E ratio of -0.31 and a beta of 0.29.

Pasithea Therapeutics (NASDAQ:KTTA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16).

Hedge Funds Weigh In On Pasithea Therapeutics

A number of hedge funds have recently bought and sold shares of KTTA. Two Sigma Investments LP purchased a new stake in shares of Pasithea Therapeutics during the 3rd quarter worth approximately $26,000. Citadel Advisors LLC boosted its holdings in Pasithea Therapeutics by 43.7% in the 3rd quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock valued at $48,000 after purchasing an additional 20,483 shares during the period. Geode Capital Management LLC grew its position in Pasithea Therapeutics by 113.9% during the fourth quarter. Geode Capital Management LLC now owns 54,495 shares of the company’s stock worth $70,000 after buying an additional 29,020 shares in the last quarter. AdvisorShares Investments LLC increased its position in shares of Pasithea Therapeutics by 18.2% in the fourth quarter. AdvisorShares Investments LLC now owns 304,721 shares of the company’s stock worth $393,000 after purchasing an additional 47,025 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Pasithea Therapeutics by 137.0% during the 4th quarter. Jane Street Group LLC now owns 59,372 shares of the company’s stock valued at $77,000 after buying an additional 34,319 shares in the last quarter. 23.92% of the stock is owned by hedge funds and other institutional investors.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.